{"organizations": ["FOPO Arena Pharmaceuticals", "Arena Pharmaceuticals"], "uuid": "7a7d48299f36f2d78d528ae95f4003d94ef0e8ef", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.pharmamedtechbi.com", "main_image": "", "site_section": "http://feeds.feedburner.com/PharmaBiotechFinancing", "section_title": "Pharma/Biotech Financing From Elsevier Business Intelligence", "url": "https://www.pharmamedtechbi.com/deals/201530520?elsca1=custom&elsca2=rss&elsca3=%3ftype%3dDeals%26advanced%3d(%2540industries%253d%2522Pharmaceuticals%2522)%2520and%2520(%2540industries%253d%2522Biotechnology%2522)%2520and%2520(%2540dealtype%253d%2522Financing%2522)", "country": "IL", "title": "Arena Pharmaceuticals closes $100.8mm FOPO", "performance_score": 0, "site": "pharmamedtechbi.com", "participants_count": 0, "title_full": "Arena Pharmaceuticals closes $100.8mm FOPO", "spam_score": 0.0, "site_type": "news", "published": "2015-07-03T02:30:00.000+03:00", "replies_count": 0, "uuid": "7a7d48299f36f2d78d528ae95f4003d94ef0e8ef"}, "author": "", "url": "https://www.pharmamedtechbi.com/deals/201530520?elsca1=custom&elsca2=rss&elsca3=%3ftype%3dDeals%26advanced%3d(%2540industries%253d%2522Pharmaceuticals%2522)%2520and%2520(%2540industries%253d%2522Biotechnology%2522)%2520and%2520(%2540dealtype%253d%2522Financing%2522)", "ord_in_thread": 0, "title": "Arena Pharmaceuticals closes $100.8mm FOPO", "locations": [], "entities": {"persons": [], "locations": [], "organizations": []}, "highlightText": "", "language": "english", "persons": [], "text": "Arena Pharmaceuticals closes $100.8mm FOPO Deal Date: Jan-01-2015 / Deal # 201530520 Executive Summary \nIn a follow-on public offering, Arena Pharmaceuticals Inc. (drugs targeting GPCRs) sold 21mm common shares at $4.81, netting $100.8mm. Arena will use the proceeds for the clinical and preclinical development of drug candidates. Its lead compound is the Phase II ralinepag, a prostacyclin receptor agonist for vascular diseases including pulmonary arterial hypertension. The company also plans to pursue additional indications for its FDA-approved chronic weight management drug Belviq (lorcaserin HCl), which is partnered with Eisai in the US under a 2010 deal, later expanded to most countries worldwide.", "external_links": [], "published": "2015-07-03T02:30:00.000+03:00", "crawled": "2015-07-03T02:38:03.000+03:00", "highlightTitle": ""}